先制医療のための疾患バイオマーカー
Saved in:
| Published in | 神経治療学 Vol. 40; no. 4; pp. 508 - 510 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本神経治療学会
2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0916-8443 2189-7824 |
| DOI | 10.15082/jsnt.40.4_508 |
Cover
| Author | 和田, 健二 |
|---|---|
| Author_xml | – sequence: 1 fullname: 和田, 健二 organization: 川崎医科大学認知症学教室 |
| BookMark | eNo9Tz1Lw0AYPqSCtXb1X6S-d7lr7hZBil9QcNH5eC-904QaJenimAShg4OT4KKDTgqOLop_5oj9G6YoLs8nPPCsk052kVlCNikMqADJttIimw04DLhu7QrpMipVEEnGO6QLig4DyXm4RvpFkRgADkAjGXVJ2FzPm_l7c_OxuK98-ebLR1-VrVjcfX1XT76-9dWzr158_eDrT1-9trhBVh1OC9v_4x452ds9Hh0E46P9w9HOOEjbbQzcxDgDMRrBwtBRSZWYRNKhEGqirLGRYJFDAOR8yBBCY52wnCpnFDLRBj2y_bubFjM8tfoyT84xv9KYz5J4avXysuag-RLa1_9FfIa5TjH8AWjUZPs |
| ContentType | Journal Article |
| Copyright | 2023 日本神経治療学会 |
| Copyright_xml | – notice: 2023 日本神経治療学会 |
| DOI | 10.15082/jsnt.40.4_508 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2189-7824 |
| EndPage | 510 |
| ExternalDocumentID | article_jsnt_40_4_40_508_article_char_ja |
| GroupedDBID | ABJNI ALMA_UNASSIGNED_HOLDINGS JSF KQ8 MOJWN RJT |
| ID | FETCH-LOGICAL-j178a-fdbfb0cab5233f18195d78fa559d9ebe7527fa00a4462a03bef5e419fb9a25a03 |
| ISSN | 0916-8443 |
| IngestDate | Wed Sep 03 06:30:18 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 4 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j178a-fdbfb0cab5233f18195d78fa559d9ebe7527fa00a4462a03bef5e419fb9a25a03 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jsnt/40/4/40_508/_article/-char/ja |
| PageCount | 3 |
| ParticipantIDs | jstage_primary_article_jsnt_40_4_40_508_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2023 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – year: 2023 text: 2023 |
| PublicationDecade | 2020 |
| PublicationTitle | 神経治療学 |
| PublicationTitleAlternate | 神経治療 |
| PublicationYear | 2023 |
| Publisher | 日本神経治療学会 |
| Publisher_xml | – name: 日本神経治療学会 |
| References | 5) Bucci M, Chiotis K, Nordberg A : Alzheimer's disease profiled by fluid and imaging markers : tau PET best predicts cognitive decline. Mol Psychiatry 26 : 5888–5898, 2021 9) Cheng L, Li W, Chen Y et al : Plasma Aβ as a biomarker for predicting Aβ–PET status in Alzheimer's disease : a systematic review with meta–analysis. J Neurol Neurosurg Psychiatry 93 : 513–520, 2022 11) Verberk IMW, Slot RE, Slot RE et al : Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol 84 : 648–658, 2018 7) Guo Y, Huang YY, Shen XN et al : Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res Ther 13 : 9, 2021 4) Hansson O, Batrla R, Brix B et al : The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement 17 : 1575–1582, 2021 1) Kasuga K, Kikuchi M, Tsukie T et al : Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid. BMJ Neurol Open. 4 : e000321, 2022 6) de Wilde A, Reimand J, Teunissen CE et al : Discordant amyloid–β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther 11 : 78, 2019 2) Shaw LM, Korecka M, Figurski M et al : Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers : Prospects and Challenges for Use in Clinical Practice. J Appl Lab Med 5 : 183–193, 2020 3) Palmqvist S, Zetterberg H, Mattsson N et al : Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85 : 1240–1249, 2015 14) Milà–Alomà M, Ashton NJ, Shekari M et al : Plasma p–tau231 and p–tau217 as state markers of amyloid–β pathology in preclinical Alzheimer's disease. Nat Med 28 : 1797–1801, 2022 8) Groot C, Smith R, Stomrud E et al : Phospho–tau with subthreshold tau–PET predicts increased tau accumulation rates in amyloid–positive individuals. Brain awac329, 2022 10) Janelidze S, Teunissen CE, Zetterberg H et al : Head–to–Head Comparison of 8 Plasma Amyloid–β 42/40 Assays in Alzheimer Disease. JAMA Neurol 78 : 1375–1382, 2021 12) Hu Y, Kirmess KM, Meyer MR et al : Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairmen. JAMA Netw Open 5 : e228392, 2022 13) Janelidze S, Palmqvist S, Leuzy A et al : Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p–tau. Alzheimers Dement 18 : 283–293, 2022 15) Syrjanen JA, Campbell MR, Algeciras–Schimnich A et al : Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement 18 : 1128–1140, 2022 16) Mielke MM, Dage JL, Frank RD et al : Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28 : 1398–1405, 2022 |
| References_xml | – reference: 3) Palmqvist S, Zetterberg H, Mattsson N et al : Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85 : 1240–1249, 2015 – reference: 5) Bucci M, Chiotis K, Nordberg A : Alzheimer's disease profiled by fluid and imaging markers : tau PET best predicts cognitive decline. Mol Psychiatry 26 : 5888–5898, 2021 – reference: 8) Groot C, Smith R, Stomrud E et al : Phospho–tau with subthreshold tau–PET predicts increased tau accumulation rates in amyloid–positive individuals. Brain awac329, 2022 – reference: 6) de Wilde A, Reimand J, Teunissen CE et al : Discordant amyloid–β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther 11 : 78, 2019 – reference: 2) Shaw LM, Korecka M, Figurski M et al : Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers : Prospects and Challenges for Use in Clinical Practice. J Appl Lab Med 5 : 183–193, 2020 – reference: 1) Kasuga K, Kikuchi M, Tsukie T et al : Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid. BMJ Neurol Open. 4 : e000321, 2022 – reference: 4) Hansson O, Batrla R, Brix B et al : The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement 17 : 1575–1582, 2021 – reference: 12) Hu Y, Kirmess KM, Meyer MR et al : Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairmen. JAMA Netw Open 5 : e228392, 2022 – reference: 10) Janelidze S, Teunissen CE, Zetterberg H et al : Head–to–Head Comparison of 8 Plasma Amyloid–β 42/40 Assays in Alzheimer Disease. JAMA Neurol 78 : 1375–1382, 2021 – reference: 15) Syrjanen JA, Campbell MR, Algeciras–Schimnich A et al : Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement 18 : 1128–1140, 2022 – reference: 14) Milà–Alomà M, Ashton NJ, Shekari M et al : Plasma p–tau231 and p–tau217 as state markers of amyloid–β pathology in preclinical Alzheimer's disease. Nat Med 28 : 1797–1801, 2022 – reference: 16) Mielke MM, Dage JL, Frank RD et al : Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28 : 1398–1405, 2022 – reference: 7) Guo Y, Huang YY, Shen XN et al : Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res Ther 13 : 9, 2021 – reference: 9) Cheng L, Li W, Chen Y et al : Plasma Aβ as a biomarker for predicting Aβ–PET status in Alzheimer's disease : a systematic review with meta–analysis. J Neurol Neurosurg Psychiatry 93 : 513–520, 2022 – reference: 11) Verberk IMW, Slot RE, Slot RE et al : Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol 84 : 648–658, 2018 – reference: 13) Janelidze S, Palmqvist S, Leuzy A et al : Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p–tau. Alzheimers Dement 18 : 283–293, 2022 |
| SSID | ssib004001787 ssib005902298 ssib000872158 ssj0003304805 ssib058494376 |
| Score | 1.9219575 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 508 |
| SubjectTerms | Alzheimer disease CSF biomarker plasma biomarker |
| Title | 先制医療のための疾患バイオマーカー |
| URI | https://www.jstage.jst.go.jp/article/jsnt/40/4/40_508/_article/-char/ja |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 神経治療学, 2023, Vol.40(4), pp.508-510 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2189-7824 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003304805 issn: 0916-8443 databaseCode: KQ8 dateStart: 20160101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07j9QwELZWR0ODQIB46wpcZnEcO7FLJ-R0QgIJ6U66LnIeLlIsCPYaus0K6QoKKiQaKKACiZIGxJ-Jlqv5B4ydZC8rKO5OWlmjmYk93rHiz7OeWYTui5IWFZXGY7TUHhOm9KQOSg-gfSELvywZs8nJj5-Eu_vs0QE_mEz-jG4tHc7zafHqv3kl5_Eq8MCvNkv2DJ5ddwoMoMG_0IKHoT2Vj3HKsYCPcITAceiIBMcxTiMsJRYUpwGgRazSnpA7jqCWPhGBcohjIEIrUoETBViSXlmxgVCDKO2JOBlE8Zozhry2c8WdfoRjZx6MEtNNIzlWD7FahwktQ1KnCyoMx8SuBTc73_aWAkuBeBy06DKK3QKzI0g3rCUSrJIzWeG6T7BU40CmH3qCdcWeppXjAW6RHmAfNn7Pd2Wh-vXMRi9tTsRo_-fdNdt_thbQsrVq65ez-ZSRKcvWj22U6-4XQ2b1MkYyZhtQzQaBzabLaoD0F6gNIdl7BE_HiBiO5OMKbBZGiI1UYUpPTsgAHyULekRpwYcNT4nu4u7wvfSlSq39DzasB9BVwxFkuL7oENXeZXSpPwptq87iK2hS66soWL0-Wh19X735cfy-aRff2sXHtlkAcfzu1-_mU7t82zaf2-ZLu_zQLn-2zVdor6H9nXQv2fX6P_bwapiM9kyZm5wUOuc0CIxvf8otI2E0nG5LCW-ViNPIaEI0YyHVJMgrwyvmS5NLTTkwrqOt2bNZdQNtw5bkm1BLE-WMGWpEURSk8CPDS0Og65so6uaYPe-qt2SnddCtcz95G120a74L1N1BW_MXh9VdgK7z_J5z9l-4EH8j |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%85%88%E5%88%B6%E5%8C%BB%E7%99%82%E3%81%AE%E3%81%9F%E3%82%81%E3%81%AE%E7%96%BE%E6%82%A3%E3%83%90%E3%82%A4%E3%82%AA%E3%83%9E%E3%83%BC%E3%82%AB%E3%83%BC&rft.jtitle=%E7%A5%9E%E7%B5%8C%E6%B2%BB%E7%99%82%E5%AD%A6&rft.au=%E5%92%8C%E7%94%B0%2C+%E5%81%A5%E4%BA%8C&rft.date=2023&rft.pub=%E6%97%A5%E6%9C%AC%E7%A5%9E%E7%B5%8C%E6%B2%BB%E7%99%82%E5%AD%A6%E4%BC%9A&rft.issn=0916-8443&rft.eissn=2189-7824&rft.volume=40&rft.issue=4&rft.spage=508&rft.epage=510&rft_id=info:doi/10.15082%2Fjsnt.40.4_508&rft.externalDocID=article_jsnt_40_4_40_508_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-8443&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-8443&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-8443&client=summon |